Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts
A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical pro...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Brady, S [verfasserIn] Wilson, JD [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Ltd ; 2004 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2004 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Journal of the European Academy of Dermatology and Venereology - European Academy of Dermatology and Venereology ; GKD-ID: 30105705, Oxford [u.a.] : Wiley-Blackwell, 1991, 18(2004), 3, Seite 0 |
| Übergeordnetes Werk: |
volume:18 ; year:2004 ; number:3 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1468-3083.2004.00918.x |
|---|
| Katalog-ID: |
NLEJ243294980 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ243294980 | ||
| 003 | DE-627 | ||
| 005 | 20210707175152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2004 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1468-3083.2004.00918.x |2 doi | |
| 035 | |a (DE-627)NLEJ243294980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Brady, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Ltd |c 2004 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. | ||
| 533 | |d 2004 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2004|||||||||| | ||
| 650 | 4 | |a genital warts | |
| 700 | 1 | |a Wilson, JD |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |a European Academy of Dermatology and Venereology ; GKD-ID: 30105705 |t Journal of the European Academy of Dermatology and Venereology |d Oxford [u.a.] : Wiley-Blackwell, 1991 |g 18(2004), 3, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926189 |w (DE-600)2022088-1 |x 1468-3083 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2004 |g number:3 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2004 |e 3 |h 0 | ||
| author_variant |
s b sb j w jw |
|---|---|
| matchkey_str |
article:14683083:2004----::lsnteedakopnuiotesoiiumdoter |
| hierarchy_sort_str |
2004 |
| publishDate |
2004 |
| allfields |
10.1111/j.1468-3083.2004.00918.x doi (DE-627)NLEJ243294980 DE-627 ger DE-627 rakwb Brady, S verfasserin aut Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| genital warts Wilson, JD verfasserin aut In European Academy of Dermatology and Venereology ; GKD-ID: 30105705 Journal of the European Academy of Dermatology and Venereology Oxford [u.a.] : Wiley-Blackwell, 1991 18(2004), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926189 (DE-600)2022088-1 1468-3083 nnns volume:18 year:2004 number:3 pages:0 http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 18 2004 3 0 |
| spelling |
10.1111/j.1468-3083.2004.00918.x doi (DE-627)NLEJ243294980 DE-627 ger DE-627 rakwb Brady, S verfasserin aut Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| genital warts Wilson, JD verfasserin aut In European Academy of Dermatology and Venereology ; GKD-ID: 30105705 Journal of the European Academy of Dermatology and Venereology Oxford [u.a.] : Wiley-Blackwell, 1991 18(2004), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926189 (DE-600)2022088-1 1468-3083 nnns volume:18 year:2004 number:3 pages:0 http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 18 2004 3 0 |
| allfields_unstemmed |
10.1111/j.1468-3083.2004.00918.x doi (DE-627)NLEJ243294980 DE-627 ger DE-627 rakwb Brady, S verfasserin aut Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| genital warts Wilson, JD verfasserin aut In European Academy of Dermatology and Venereology ; GKD-ID: 30105705 Journal of the European Academy of Dermatology and Venereology Oxford [u.a.] : Wiley-Blackwell, 1991 18(2004), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926189 (DE-600)2022088-1 1468-3083 nnns volume:18 year:2004 number:3 pages:0 http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 18 2004 3 0 |
| allfieldsGer |
10.1111/j.1468-3083.2004.00918.x doi (DE-627)NLEJ243294980 DE-627 ger DE-627 rakwb Brady, S verfasserin aut Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| genital warts Wilson, JD verfasserin aut In European Academy of Dermatology and Venereology ; GKD-ID: 30105705 Journal of the European Academy of Dermatology and Venereology Oxford [u.a.] : Wiley-Blackwell, 1991 18(2004), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926189 (DE-600)2022088-1 1468-3083 nnns volume:18 year:2004 number:3 pages:0 http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 18 2004 3 0 |
| allfieldsSound |
10.1111/j.1468-3083.2004.00918.x doi (DE-627)NLEJ243294980 DE-627 ger DE-627 rakwb Brady, S verfasserin aut Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| genital warts Wilson, JD verfasserin aut In European Academy of Dermatology and Venereology ; GKD-ID: 30105705 Journal of the European Academy of Dermatology and Venereology Oxford [u.a.] : Wiley-Blackwell, 1991 18(2004), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926189 (DE-600)2022088-1 1468-3083 nnns volume:18 year:2004 number:3 pages:0 http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 18 2004 3 0 |
| source |
In Journal of the European Academy of Dermatology and Venereology 18(2004), 3, Seite 0 volume:18 year:2004 number:3 pages:0 |
| sourceStr |
In Journal of the European Academy of Dermatology and Venereology 18(2004), 3, Seite 0 volume:18 year:2004 number:3 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
genital warts |
| isfreeaccess_bool |
false |
| container_title |
Journal of the European Academy of Dermatology and Venereology |
| authorswithroles_txt_mv |
Brady, S @@aut@@ Wilson, JD @@aut@@ |
| publishDateDaySort_date |
2004-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926189 |
| id |
NLEJ243294980 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ243294980</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707175152.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1468-3083.2004.00918.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ243294980</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brady, S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">genital warts</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilson, JD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="a">European Academy of Dermatology and Venereology ; GKD-ID: 30105705</subfield><subfield code="t">Journal of the European Academy of Dermatology and Venereology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1991</subfield><subfield code="g">18(2004), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926189</subfield><subfield code="w">(DE-600)2022088-1</subfield><subfield code="x">1468-3083</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2004</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Brady, S |
| spellingShingle |
Brady, S misc genital warts Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts |
| authorStr |
Brady, S |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926189 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1468-3083 |
| topic_title |
Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts genital warts |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| topic |
misc genital warts |
| topic_unstemmed |
misc genital warts |
| topic_browse |
misc genital warts |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
Journal of the European Academy of Dermatology and Venereology |
| hierarchy_parent_id |
NLEJ243926189 |
| hierarchy_top_title |
Journal of the European Academy of Dermatology and Venereology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926189 (DE-600)2022088-1 |
| title |
Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts |
| ctrlnum |
(DE-627)NLEJ243294980 |
| title_full |
Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts |
| author_sort |
Brady, S |
| journal |
Journal of the European Academy of Dermatology and Venereology |
| journalStr |
Journal of the European Academy of Dermatology and Venereology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2004 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Brady, S Wilson, JD |
| container_volume |
18 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Brady, S |
| doi_str_mv |
10.1111/j.1468-3083.2004.00918.x |
| author2-role |
verfasserin |
| title_sort |
closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts |
| title_auth |
Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts |
| abstract |
A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. |
| abstractGer |
A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. |
| abstract_unstemmed |
A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
3 |
| title_short |
Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts |
| url |
http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x |
| remote_bool |
true |
| author2 |
Wilson, JD |
| author2Str |
Wilson, JD |
| ppnlink |
NLEJ243926189 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1111/j.1468-3083.2004.00918.x |
| up_date |
2024-07-06T04:58:55.876Z |
| _version_ |
1803804408152064000 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ243294980</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707175152.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1468-3083.2004.00918.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ243294980</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brady, S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A retrospective case-note audit of 74 patients with 81 treatment episodes of anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority of patients had failed to clear their warts with other treatments, had recurrences after other treatments, or had other medical problems complicating their genital wart treatment. The overall clinically confirmed complete clearance rate was 33%. This is lower than other published data, but may be so because it includes patients with immunosuppression and difficult-to-treat warts. The complete clearance rate in immunocompetent patients was 37%. In addition, in this audit of clinical practice 17% of the patients did not return for full response to be assessed. The complete clearance rate in those who were able to tolerate treatment and who returned for follow-up was 45%. Based on the results of the audit we have extended the indications for the use of imiquimod in the clinic treatment guidelines. Patients are now offered imiquimod if six or more episodes of other treatments fail to give a good response. Earlier treatment with imiquimod is also offered to those patients with recurrent anogenital warts, and it is recommended as a first-line therapy for patients with multiple keratinized warts.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">genital warts</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilson, JD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="a">European Academy of Dermatology and Venereology ; GKD-ID: 30105705</subfield><subfield code="t">Journal of the European Academy of Dermatology and Venereology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1991</subfield><subfield code="g">18(2004), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926189</subfield><subfield code="w">(DE-600)2022088-1</subfield><subfield code="x">1468-3083</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1468-3083.2004.00918.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2004</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.397518 |